

Table S1. Clinical characteristics and serum levels of CMT-associated AAbs in 90 CMT dogs enrolled in the overall survival analysis

Characteristics	Case number	TYMS-AAb		IGFBP5-AAb		HAPLN1-AAb		AGR2-AAb	
		Median (range)	Mean \pm SD	Median (range)	Mean \pm SD	Median (range)	Mean \pm SD	Median (range)	Mean \pm SD
MT									
BMT	20	0.338 (0.189–0.598)	0.355 \pm 0.111	0.294 (0.158–0.502)	0.294 \pm 0.085	0.326 (0.203–0.603)	0.350 \pm 0.093	0.262 (0.126–0.515)	0.262 \pm 0.103
MMT	70	0.383 (0.273–0.733)	0.406 \pm 0.099	0.329 (0.179–0.532)	0.338 \pm 0.078	0.366 (0.227–1.017)	0.395 \pm 0.120	0.275 (0.139–0.533)	0.299 \pm 0.111
Clinical stage (MMT)									
I	34	0.379 (0.289–0.733)	0.407 \pm 0.107	0.307 (0.179–0.532)	0.329 \pm 0.093	0.381 (0.273–1.017)	0.413 \pm 0.138	0.274 (0.140–0.533)	0.294 \pm 0.106
II	9	0.354 (0.288–0.450)	0.367 \pm 0.052	0.323 (0.244–0.442)	0.334 \pm 0.053	0.361 (0.227–0.463)	0.355 \pm 0.022	0.287 (0.152–0.517)	0.314 \pm 0.132
III	16	0.422 (0.273–0.605)	0.413 \pm 0.084	0.367 (0.258–0.506)	0.362 \pm 0.057	0.329 (0.249–0.545)	0.371 \pm 0.093	0.267 (0.147–0.479)	0.293 \pm 0.113
IV	7	0.390 (0.282–0.728)	0.439 \pm 0.153	0.338 (0.218–0.424)	0.338 \pm 0.071	0.474 (0.289–0.661)	0.453 \pm 0.133	0.287 (0.139–0.529)	0.315 \pm 0.147
V	4	0.398 (0.344–0.462)	0.400 \pm 0.052	0.323 (0.230–0.411)	0.323 \pm 0.075	0.324 (0.287–0.358)	0.323 \pm 0.034	0.279 (0.246–0.395)	0.300 \pm 0.070